FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384525417> ?p ?o ?g. }

• W4384525417 endingPage "1192" @default.
• W4384525417 startingPage "1192" @default.
• W4384525417 abstract "(1) Background: Piperacillin/tazobactam is a broad-spectrum antimicrobial encompassing most Gram-positive and Gram-negative aerobic and anaerobic bacteria. The inappropriate use of such broad-spectrum antibiotics is an important contributor to the rising rates of antimicrobial drug resistance worldwide. Drug utilization evaluation studies and pharmacists' interventions are vital to assess, develop, and promote the rational use of antibiotics. This drug utilization study aimed to evaluate the current utilization practice of piperacillin/tazobactam in a hospital setting and assess the impact of pharmacist intervention in improving its appropriate use. (2) Methodology: In this study, we used a retrospective cohort and a prospective cohort, a cross-sectional, observational method. It included a retrospective (Cycle A/pre-intervention-CycA) phase followed by an educational interventional phase conducted by the pharmacists. During the 2 months of educational intervention, pharmacists used several methods, including workshops, lectures, oral presentations, and the development and reinforcement of clinical pathways to promote the judicious use of piperacillin/tazobactam. This was followed by a prospective (Cycle B/post-intervention-CycB) phase to improve piperacillin/tazobactam usage appropriateness. The appropriateness criteria for this drug utilization evaluation were established based on antimicrobial guidelines, the published literature, the institutional antibiogram, consultation from the antimicrobial stewardship committee, and the product monograph (Tazocin). The appropriateness of CycA and CycB patients was compared using the measurable elements, including indication and dose based on renal function, timely order for cultures, de-escalation, and use of extended infusion protocol. (3) Results: The study population comprised 100 patients in both CycA and CycB. The mean age of the patients was 66.28 ± 16.15 and 67.35 ± 17.98, and the ratios of men to women were found to be 49:51 and 61:39 in CycA and CycB, respectively. It was observed that inappropriate usage was high in CycA patients, and the appropriateness was improved in CycB patients. A total of 31% of inappropriate empirical broad-spectrum use was found in CycA, and it was reduced to 12% in CycB patients. The transition of appropriateness was observed in all measurable criteria, which includes the optimized dose according to the renal function (CycA = 49% to CycB = 94%), timely bacterial culture orders (CycA = 47% to CycB = 74%), prompt de-escalation (CycA = 31% to CycB = 53%), and adherence to extended infusion institutional guidelines (CycA = 34% to CycB = 86%). (4) Conclusions: The study highlighted important aspects of inappropriate piperacillin/tazobactam use. This can be considerably improved by proper education and timely interventions based on the pharmacists' vigilant approach. The study results emphasized the need for surveillance of piperacillin/tazobactam usage by conducting similar drug utilization evaluations and practice to improve quality and safety in healthcare organizations globally." @default.
• W4384525417 created "2023-07-18" @default.
• W4384525417 creator A5005294867 @default.
• W4384525417 creator A5019031466 @default.
• W4384525417 creator A5021734439 @default.
• W4384525417 creator A5068924325 @default.
• W4384525417 creator A5072404913 @default.
• W4384525417 creator A5074575403 @default.
• W4384525417 creator A5082086437 @default.
• W4384525417 creator A5084773050 @default.
• W4384525417 creator A5086730979 @default.
• W4384525417 creator A5092485814 @default.
• W4384525417 date "2023-07-15" @default.
• W4384525417 modified "2023-09-27" @default.
• W4384525417 title "Drug Utilization Evaluation and Impact of Pharmacist Interventions on Optimization of Piperacillin/Tazobactam Use: A Retrospective Analysis and Prospective Audit" @default.
• W4384525417 cites W1560331648 @default.
• W4384525417 cites W1807094295 @default.
• W4384525417 cites W1845553064 @default.
• W4384525417 cites W1967587362 @default.
• W4384525417 cites W1988896786 @default.
• W4384525417 cites W2031140786 @default.
• W4384525417 cites W2046762565 @default.
• W4384525417 cites W2053430308 @default.
• W4384525417 cites W2064618548 @default.
• W4384525417 cites W2073122282 @default.
• W4384525417 cites W2074425904 @default.
• W4384525417 cites W2092802285 @default.
• W4384525417 cites W2123859227 @default.
• W4384525417 cites W2136808174 @default.
• W4384525417 cites W2139370844 @default.
• W4384525417 cites W2145273918 @default.
• W4384525417 cites W2165153850 @default.
• W4384525417 cites W2277317772 @default.
• W4384525417 cites W2298261704 @default.
• W4384525417 cites W2583549666 @default.
• W4384525417 cites W2604899547 @default.
• W4384525417 cites W2752339811 @default.
• W4384525417 cites W2775901474 @default.
• W4384525417 cites W2779019546 @default.
• W4384525417 cites W2794276483 @default.
• W4384525417 cites W2951800938 @default.
• W4384525417 cites W3024119572 @default.
• W4384525417 cites W3035919630 @default.
• W4384525417 cites W3087916810 @default.
• W4384525417 cites W3088020886 @default.
• W4384525417 cites W3129562214 @default.
• W4384525417 cites W3139285451 @default.
• W4384525417 cites W3202964273 @default.
• W4384525417 cites W4238527420 @default.
• W4384525417 cites W4283692770 @default.
• W4384525417 cites W4283805331 @default.
• W4384525417 cites W4319303364 @default.
• W4384525417 doi "https://doi.org/10.3390/antibiotics12071192" @default.
• W4384525417 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37508288" @default.
• W4384525417 hasPublicationYear "2023" @default.
• W4384525417 type Work @default.
• W4384525417 citedByCount "0" @default.
• W4384525417 crossrefType "journal-article" @default.
• W4384525417 hasAuthorship W4384525417A5005294867 @default.
• W4384525417 hasAuthorship W4384525417A5019031466 @default.
• W4384525417 hasAuthorship W4384525417A5021734439 @default.
• W4384525417 hasAuthorship W4384525417A5068924325 @default.
• W4384525417 hasAuthorship W4384525417A5072404913 @default.
• W4384525417 hasAuthorship W4384525417A5074575403 @default.
• W4384525417 hasAuthorship W4384525417A5082086437 @default.
• W4384525417 hasAuthorship W4384525417A5084773050 @default.
• W4384525417 hasAuthorship W4384525417A5086730979 @default.
• W4384525417 hasAuthorship W4384525417A5092485814 @default.
• W4384525417 hasBestOaLocation W43845254171 @default.
• W4384525417 hasConcept C104863432 @default.
• W4384525417 hasConcept C126322002 @default.
• W4384525417 hasConcept C159110408 @default.
• W4384525417 hasConcept C167135981 @default.
• W4384525417 hasConcept C177713679 @default.
• W4384525417 hasConcept C2776040555 @default.
• W4384525417 hasConcept C2777637488 @default.
• W4384525417 hasConcept C2777858937 @default.
• W4384525417 hasConcept C2778193466 @default.
• W4384525417 hasConcept C2778266534 @default.
• W4384525417 hasConcept C2779457091 @default.
• W4384525417 hasConcept C2908647359 @default.
• W4384525417 hasConcept C501593827 @default.
• W4384525417 hasConcept C523546767 @default.
• W4384525417 hasConcept C54355233 @default.
• W4384525417 hasConcept C71924100 @default.
• W4384525417 hasConcept C86803240 @default.
• W4384525417 hasConcept C89423630 @default.
• W4384525417 hasConcept C94665300 @default.
• W4384525417 hasConcept C99454951 @default.
• W4384525417 hasConceptScore W4384525417C104863432 @default.
• W4384525417 hasConceptScore W4384525417C126322002 @default.
• W4384525417 hasConceptScore W4384525417C159110408 @default.
• W4384525417 hasConceptScore W4384525417C167135981 @default.
• W4384525417 hasConceptScore W4384525417C177713679 @default.
• W4384525417 hasConceptScore W4384525417C2776040555 @default.
• W4384525417 hasConceptScore W4384525417C2777637488 @default.
• W4384525417 hasConceptScore W4384525417C2777858937 @default.
• W4384525417 hasConceptScore W4384525417C2778193466 @default.

• next